Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 13, 2012 - Issue 17
Submit an article Journal homepage
1,033
Views
27
CrossRef citations to date
0
Altmetric
Drug Evaluations

Vemurafenib for the treatment of melanoma

Emmet John JordanWaterford Regional Hospital, Department of Medical Oncology, Dunmore Road, Waterford, Ireland
&
Catherine M KellyUniversity College Dublin, Mater Misericordiae University Hospital, Consultant Medical Oncologist, Department of Medical Oncology, Eccles Street, Dublin 7, Ireland+018032000; +018032113; [email protected]
Pages 2533-2543 | Published online: 24 Oct 2012

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yong Ling, Zhi-You Hao, Dong Liang, Chun-Lei Zhang, Yan-Fei Liu & Yan Wang. (2021) The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Design, Development and Therapy 15, pages 4289-4338.
Read now

Articles from other publishers (26)

Xiaocong Chen, Yang An, Mengsi Tan, Dongrui Xie, Ling Liu & Benjin Xu. (2023) Biological functions and research progress of eIF4E. Frontiers in Oncology 13.
Crossref
Sowjanya Thatikonda, Venkatesh Pooladanda, Ramya Tokala, Shankaraiah Nagula & Chandraiah Godugu. (2023) Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells. Toxicology in Vitro 89, pages 105579.
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer 205 411 .
Angela Clerk, Daniel N. Meijles, Michelle A. HardymanStephen J. FullerSonia P. Chothani, Joshua J. CullSusanna T.E. CooperHajed O. AlharbiKonstantinos VanezisLeanne E. FelkinThomais MarkouSamuel J. LeonardSpencer W. ShawOwen J.L. Rackham, Stuart A. Cook, Peter E. GlennonMary N. SheppardJohn C. Sembrat, Mauricio Rojas, Charles F. McTiernan, Paul J. BartonPeter H. Sugden. (2022) Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo . Biochemical Journal 479:3, pages 401-424.
Crossref
Liming Yu, Fan Peng, Xue Dong, Ying Chen, Dongdong Sun, Shuai Jiang & Chao Deng. (2020) Sex-Determining Region Y Chromosome-Related High-Mobility-Group Box 10 in Cancer: A Potential Therapeutic Target. Frontiers in Cell and Developmental Biology 8.
Crossref
Serena L'Abbate, Ilaria Russo & Claudia Kusmic. (2020) The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know. Life Sciences 255, pages 117843.
Crossref
Ioana Baldea, Lorin Giurgiu, Ioana Diana Teacoe, Diana Elena Olteanu, Florin Catalin Olteanu, Simona Clichici & Gabriela Adriana Filip. (2019) Photodynamic Therapy in Melanoma - Where do we Stand?. Current Medicinal Chemistry 25:40, pages 5540-5563.
Crossref
Ashley Neiweem, Denis Jusufbegovic & Arun D. Singh. 2019. Clinical Ophthalmic Oncology. Clinical Ophthalmic Oncology 143 159 .
Jialin Duan, Jingwen Tao, Maocai Zhai, Chengpeng Li, Ning Zhou, Jiagao Lv, Lin Wang, Li Lin & Rong Bai. (2018) Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget 9:39, pages 25738-25749.
Crossref
Maxim Sorokin, Roman Kholodenko, Anna Grekhova, Maria Suntsova, Margarita Pustovalova, Natalia Vorobyeva, Irina Kholodenko, Galina Malakhova, Andrew Garazha, Artem Nedoluzhko, Raif Vasilov, Elena Poddubskaya, Olga Kovalchuk, Leila Adamyan, Vladimir Prassolov, Daria Allina, Denis Kuzmin, Kirill Ignatev, Andreyan Osipov & Anton Buzdin. (2017) Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. Oncotarget 9:4, pages 5111-5124.
Crossref
Stephen L. Vance, Hannah M. Singer, David Silvers, Sameera Husain & Filamer Kabigting. (2017) Delayed-onset vemurafenib-induced panniculitis. JAAD Case Reports 3:5, pages 384-386.
Crossref
So Young Kim, Dongxu Kang, Hye Jin Choi, Yeonsoo Joo, Joo-Hang Kim & Jae J. Song. (2017) Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation. Oncotarget 8:9, pages 15858-15877.
Crossref
Michael B. Nicholl, Xuhui Chen, Chenglu Qin, Qian Bai, Ziwen Zhu, Matthew R. Davis & Yujiang Fang. (2016) IL-32α has differential effects on proliferation and apoptosis of human melanoma cell lines. Journal of Surgical Oncology 113:4, pages 364-369.
Crossref
Jae-Young Kim, HyunYoung Kim, Jung-Hwan Lim & Woong Nam. (2015) Treatment modality of malignant melanoma that metastasized to the mandible and multiple organs: A rare case report and the literature review. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 27:3, pages 398-401.
Crossref
Antonio M. Grimaldi, Ester Simeone, Marco Palla, Lucia Festino, Corrado Caracò, Nicola Mozzillo, Antonella Petrillo, Paolo Muto & Paolo A. Ascierto. (2015) Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs 26:4, pages 464-468.
Crossref
Gabriel Gazzé. (2015) Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma. Melanoma Management 2:1, pages 75-82.
Crossref
Julie Marchant, Alain Mange, Marion Larrieux, Valérie Costes & Jérôme Solassol. (2014) Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing. BMC Cancer 14:1.
Crossref
Shivani Felicia Chandrakumar & Jensen Yeung. (2014) Cutaneous Adverse Events during Vemurafenib Therapy. Journal of Cutaneous Medicine and Surgery 18:4, pages 223-228.
Crossref
Emma Shtivelman, Michael A. Davies, Patrick Hwu, James Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty & David E. Fisher. (2014) Pathways and therapeutic targets in melanoma. Oncotarget 5:7, pages 1701-1752.
Crossref
Michael P Brown & Georgina V Long. (2014) The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation . Asia-Pacific Journal of Clinical Oncology 10, pages 1-15.
Crossref
Denis Jusufbegovic, Pierre L. Triozzi & Arun D. Singh. 2014. Clinical Ophthalmic Oncology. Clinical Ophthalmic Oncology 123 132 .
Jack Murrell & Ruth Board. (2013) The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. Cancer Treatment Reviews 39:8, pages 833-838.
Crossref
Mathieu Capovilla. (2013) Effets secondaires carcinogènes et résistances aux thérapies ciblées anti-BRAF. Annales de Pathologie 33:6, pages 375-385.
Crossref
Antonia L. Pritchard & Nicholas K. Hayward. (2013) Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance. Clinical Cancer Research 19:9, pages 2301-2309.
Crossref
Idit Melnik, Michal Lotem & Boris Yoffe. (2013) A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine 2013, pages 1-3.
Crossref
Inken Wierstra. 2013. 191 419 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.